Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that its Phase 3 study of VQW-765 in adults with social anxiety disorder failed to meet its primary endpoint. The company has placed the development program on hold while it analyzes the complete dataset.
The randomized, double-blind and placebo-controlled Study 3201 enrolled 546 adults between the ages of 18 and 65 at approximately 30 clinical sites in the United States. Participants received a single oral dose of VQW-765 or a placebo before undergoing the Trier Social Stress Test, which required them to prepare and deliver an interview-style presentation before an unresponsive panel.
The study’s primary endpoint measured participants’ self-reported distress during the presentation phase using the Subjective Units of Distress Scale.
Among female participants, the mean distress score was 65.6 for the VQW-765 group and 66.0 for the placebo group. The difference was not statistically significant, with a p-value of 0.8899.
The trial also failed its key secondary endpoint in the full population of male and female participants. The mean score was 64.7 with VQW-765 and 63.8 with placebo, producing a p-value of 0.6605.
Study 3201 was designed to confirm an efficacy signal observed in an earlier Phase 2 trial involving people with performance anxiety. The new results did not reproduce those findings.
“We are disappointed that Study 3201 did not confirm the earlier Phase II findings,” President and CEO Mihael H. Polymeropoulos said.
Vanda reported that VQW-765 was safe and well tolerated, consistent with earlier studies. The company did not provide detailed adverse-event results in its topline announcement.
VQW-765, previously known as AQW-051, is an oral small-molecule partial agonist of the alpha-7 nicotinic acetylcholine receptor. Vanda licensed the compound from Novartis and has been evaluating it as an on-demand treatment for acute anxiety associated with social situations.
The failed trial substantially weakens the clinical rationale for advancing VQW-765 in social anxiety disorder. However, the setback is limited to one development program. Vanda remains a commercial-stage pharmaceutical company with approved products, including Fanapt, Hetlioz, Ponvory and Nereus.
Financial capacity remains relevant as the company evaluates its pipeline. Vanda reported $50.5 million in second-quarter 2026 net product sales and a quarterly net loss of $62.5 million. Cash, cash equivalents and marketable securities totaled $170 million as of June 30, down from $263.8 million at the end of 2025.
Upcoming Catalysts
- Completion of Vanda’s analysis of the full Study 3201 dataset
- A decision on whether to discontinue, redesign or redirect the VQW-765 program
- Possible presentation or publication of detailed efficacy and safety results
- Vanda’s next quarterly financial and pipeline update
Sources
- Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program — October 14, 2026
- Study 3201 Clinical-Trial Record, NCT07221578 — ClinicalTrials.gov
- Vanda Pharmaceuticals Second-Quarter 2026 Financial Results
- Vanda Pharmaceuticals Form 10-Q for the Quarter Ended June 30, 2026 — SEC
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, SEC filings and the federal clinical-trial registry. The security discussed is Vanda Pharmaceuticals Inc. (Nasdaq: VNDA). Biotech Stocks Daily has not received compensation from Vanda Pharmaceuticals, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in the security discussed at the time of publication.
Sources used include Vanda’s October 14, 2026 clinical-program update, its second-quarter financial results, its SEC Form 10-Q for the quarter ended June 30, 2026 and the ClinicalTrials.gov record for Study 3201. Statements concerning VQW-765’s mechanism, safety and development status originated primarily from Vanda and have not been independently validated by Biotech Stocks Daily.
VQW-765 remains investigational and has not been approved by the FDA for social anxiety disorder, performance anxiety or any other indication. Study 3201 failed both its primary endpoint and its key secondary endpoint. The program is on hold, and further analysis may not support continued development. The company’s statement that VQW-765 was safe and well tolerated was based on its topline summary, which did not include detailed adverse-event results.
Financial information is reported in U.S. dollars and reflects Vanda’s position as of June 30, 2026. The company reported a quarterly net loss, substantial research and commercialization expenses and a decline in cash and marketable securities during the first half of 2026. Historical product sales and cash balances do not guarantee future operating performance or sufficient funding for every development program.
Biotechnology and pharmaceutical securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
